Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis
about
Hepatitis C virus infection and prisoners: Epidemiology, outcome and treatmentValue of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic EvidenceClinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis.Hospital admissions for HIV-infected prisoners in Italy.Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.Performance of Risk-Based and Birth-Cohort Strategies for Identifying Hepatitis C Virus Infection Among People Entering Prison, Wisconsin, 2014.Epidemiology of Infectious Disease-Related Death After Release from Prison, Washington State, United States, and Queensland, Australia: A Cohort StudyHepatitis C in Australian prisons: a national needs assessment.Feasibility of Treating Hepatitis C in a Transient Jail Population.Rethinking cost-effectiveness in the era of zero healthcare spending growth.Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.Blood-borne viral co-infections among human immunodeficiency virus-infected inmates.Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection.When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs.The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care.A comparison of liver disease mortality with HIV and overdose mortality among Georgia prisoners and releasees: a 2-decade cohort study of prisoners incarcerated in 1991.Cost-Effectiveness of Treatments for Genotype 1 Hepatitis C Virus Infection in non-VA and VA Populations.Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses.Population Health and Cost-Effectiveness Implications of a "Treat All" Recommendation for HCV: A Review of the Model-Based EvidenceStrategies for the elimination of hepatitis C virus infection as a public health threat in the United States
P2860
Q26785981-EAC62D03-7DCF-4B2C-9314-FA46AAE871DAQ28072257-DBCCC7C0-B7EE-413B-8FDB-F60CF0D14103Q30248944-E0195336-63AD-4516-B470-F898367B3427Q33442442-764BDF6E-4B8B-45C5-9B68-04559F408FC4Q35736293-616FE28E-6AFD-4D8A-8272-8E10D6D22309Q35915999-414ABEBD-B110-4596-A681-2DE88658645EQ36862066-77B5494B-2B93-48EC-A730-D2A2D64E6AE0Q37075712-79E74A99-9E44-4350-97FD-89FB3C0D8B26Q37075726-4602FCDD-14FD-4CBB-8D0E-4D30882F6E24Q38382431-AC6E9176-020A-4262-BC87-DCC06CAF9EE0Q38602739-47E709BD-8D51-4747-8A74-A3BD1912C5C3Q38623992-2927834E-8E7D-44E0-BC04-E4FF7489884BQ38691333-E7499E12-A2A3-4C7D-804A-192C115F127FQ38755073-1ED406BD-C463-45B0-8758-F6EB9FAA9243Q38983274-4274B3F5-747C-4E67-80BB-BC01A9940509Q39739900-DFC12D96-687F-43D6-A959-1841A9E13E60Q40072613-8E497FFF-1C0E-41BC-86E2-2A9442E24704Q41493589-A2E6E6C7-29D5-456C-9CD3-1844C28A4857Q42368917-02D0F9B4-274A-4769-8F7D-B6005DD9F50BQ47115868-3D39CF18-E211-4915-8CC5-62B262FC19E1Q53572231-BC4EE0B2-60FF-4803-A09F-0EE24DBF7968Q54984374-F8E3497C-2D51-4138-9238-E2BA8C9D0AC3Q55280669-F9DB158D-6F5E-4868-9E5A-6865CC107E1CQ57145115-39990D53-C46C-488A-836A-9A0100EA1EDAQ57193075-48DAC1D3-24BE-4290-9189-01A722EDC4D4
P2860
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@ast
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@en
type
label
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@ast
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@en
prefLabel
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@ast
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@en
P2860
P356
P1476
Sofosbuvir-based treatment reg ...... a cost-effectiveness analysis
@en
P2093
Daena Watcha
P2860
P304
P356
10.7326/M14-0602
P407
P577
2014-10-01T00:00:00Z